Trial Profile
A Real-world, retrospective study of efficacy and safety outcomes of Panobinostat in patients with Relapsed/Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jan 2017
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 19 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology